AETN 最新10-Q变化
将 AETN 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-05-19 与上一份 10-Q · 2025-11-13
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +13 | −18 | ~1 | 5 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 2 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼、风险因素、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-05-19
On February 17, 2026, the Company entered into a merger agreement with Aeternum Health LLC, pursuant to which Aeternum Health will merge into Shorepower, with Shorepower as the surviving entity. Upon closing, Shorepower’s CEO and sole director, Jeff Kim, will resign and appoint Paul Mann, Aeternum H…
As consideration for the merger, the Company will issue shares representing 51% ownership and 2,000,000 shares of Series B preferred stock (with super voting rights) to Paul Mann. Aeternum Health will contribute assets including intellectual property and data related to a peptide-based longevity tre…
In March 2026, the Company changed its name to Aeternum Health, Inc. and its trading symbol to AETN. Effective April 3, 2026, the Company increased its authorized shares from 100 million to 250 million. The merger is subject to customary closing conditions, including receipt of the audited financial…
For the three months ended March 31, 2026 compared to the three months ended March 31, 2025
We had total revenue of $2,260 for the three months ended March 31, 2026, compared to $164,657 for the three months ended March 31, 2025, a decrease of $162,397 or 98.6%. We had costs of revenue of $13,461 and $38,383, respectively, and a deduction for revenue share of $776 and $922, respectively, f…
相对上期删除的文字 · 来源:10-Q · 2025-11-13
For the three months ended September 30, 2025 compared to the three months ended September 30, 2024
We had total revenue of $8,345 for the three months ending September 30, 2025 compared to $15,442 for the three months ended September 30, 2024, a decrease of $7,097 or 46%. We had costs of revenue of $15,527 and $28,904, respectively, and a deduction for revenue share of $1,435 and $1,422, respecti…
For the three months ending September 30, 2025, the company incurred $14,140 of professional fees compared to $13,000 for the three months ending September 30, 2024, an increase of $1,140 or 8.8%. Professional fees generally consist of audit, legal, accounting and investor relation fees. In the curr…
For the three months ended September 30, 2025, the company incurred $37,686 of general and administrative expense (“G&A”) compared to $12,045 for the three months ended September 30, 2024, an increase of $25,641 or 212.9%.
For the three months ending September 30, 2025, we recognized $10,500 of consulting expense, compared to $20,155 in the prior period, a decrease of $9,655 or 47.9%.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议